Literature DB >> 9705397

Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media.

M A Pfaller1, S A Messer, A Karlsson, A Bolmström.   

Abstract

The performance of the Etest for fluconazole susceptibility testing of 402 yeast isolates was assessed against the National Committee for Clinical Laboratory Standards (NCCLS) microdilution broth method. The NCCLS method employed RPMI 1640 broth medium, and MICs were read after incubation for 48 h at 35 degrees C. Etest MICs were determined with RPMI agar containing 2% glucose (RPG), Casitone agar (CAS), and Mueller-Hinton agar (MHA) and were read after incubation for 48 h at 35 degrees C. The yeast isolates included Candida albicans (n = 161), Candida glabrata (n = 41), Candida tropicalis (n = 35), Candida parapsilosis (n = 29), Candida krusei (n = 32), Candida lusitaniae (n = 31), Candida species (n = 19), Cryptococcus neoformans (n = 40), and miscellaneous yeast species (n = 14). The Etest results correlated well with reference MICs. Overall agreement was 94% with RPG, 97% with CAS, and 53% with MHA. When RPG was used, agreement ranged from 89% for Candida spp. to 100% for C. krusei. When CAS was utilized, agreement ranged from 93% for Cryptococcus neoformans to 100% for C. tropicalis, C. parapsilosis, C. lusitaniae, Candida spp., and miscellaneous yeast species. With MHA, agreement ranged from 17% for C. parapsilosis to 90% for C. krusei. Both RPG and CAS supported growth of all yeast species, whereas growth on MHA was comparatively weaker. Etest results were somewhat easier to read on CAS. The Etest method using either RPG or CAS, but not MHA, appears to be a viable alternative to the NCCLS reference method for determining fluconazole susceptibilities of yeasts.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9705397      PMCID: PMC105167     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  18 in total

1.  Multisite reproducibility of the Etest MIC method for antifungal susceptibility testing of yeast isolates.

Authors:  M A Pfaller; S A Messer; A Bolmström; F C Odds; J H Rex
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

2.  Fluconazole disk diffusion procedure for determining susceptibility of Candida species.

Authors:  A L Barry; S D Brown
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

3.  Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique.

Authors:  S C Chen; M L O'Donnell; S Gordon; G L Gilbert
Journal:  J Antimicrob Chemother       Date:  1996-02       Impact factor: 5.790

4.  Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose.

Authors:  A Espinel-Ingroff; M Pfaller; M E Erwin; R N Jones
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

5.  Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine.

Authors:  M A Pfaller; M Bale; B Buschelman; M Lancaster; A Espinel-Ingroff; J H Rex; M G Rinaldi; C R Cooper; M R McGinnis
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

6.  Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates.

Authors:  A Wanger; K Mills; P W Nelson; J H Rex
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

7.  Comparison of broth macrodilution, broth microdilution, and E test antifungal susceptibility tests for fluconazole.

Authors:  D L Sewell; M A Pfaller; A L Barry
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

8.  Evaluation of the E test system versus a microtitre broth method for antifungal susceptibility testing of yeasts against fluconazole and itraconazole.

Authors:  A L Colombo; F Barchiesi; D A McGough; A W Fothergill; M G Rinaldi
Journal:  J Antimicrob Chemother       Date:  1995-07       Impact factor: 5.790

9.  Evaluation of a novel colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates.

Authors:  M A Pfaller; A L Barry
Journal:  J Clin Microbiol       Date:  1994-08       Impact factor: 5.948

10.  Use of a colorimetric system for yeast susceptibility testing.

Authors:  R N Tiballi; X He; L T Zarins; S G Revankar; C A Kauffman
Journal:  J Clin Microbiol       Date:  1995-04       Impact factor: 5.948

View more
  28 in total

1.  Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species.

Authors:  M A Pfaller; S A Messer; K Mills; A Bolmström; R N Jones
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

2.  Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole.

Authors:  Madonna J Matar; Luis Ostrosky-Zeichner; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

3.  Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole.

Authors:  M A Pfaller; D J Diekema; L Boyken; S A Messer; S Tendolkar; R J Hollis
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

4.  Evaluation of disk diffusion method for determining eberconazole susceptibility of dermatophytes and influence of culture medium.

Authors:  Belkys Fernández-Torres; Isabel Inza; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

5.  Effect of culture medium on the disk diffusion method for determining antifungal susceptibilities of dermatophytes.

Authors:  Belkys Fernández-Torres; Alfonso Carrillo-Muñoz; Isabel Inza; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

6.  In vitro activity of A-192411.29, a novel antifungal lipopeptide.

Authors:  A M Nilius; P M Raney; D M Hensey-Rudloff; W Wang; Q Li; R K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

7.  Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.

Authors:  M A Pfaller; D J Diekema; S A Messer; L Boyken; R J Hollis
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

8.  Susceptibility testing of fluconazole by the NCCLS broth macrodilution method, E-test, and disk diffusion for application in the routine laboratory.

Authors:  Inge Vandenbossche; Mario Vaneechoutte; Marleen Vandevenne; Thierry De Baere; Gerda Verschraegen
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

9.  Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species.

Authors:  Joseph Meletiadis; Johan W Mouton; Jacques F G M Meis; Bianca A Bouman; Paul E Verweij
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

10.  Multicenter comparative evaluation of six commercial systems and the national committee for clinical laboratory standards m27-a broth microdilution method for fluconazole susceptibility testing of Candida species.

Authors:  G Morace; G Amato; F Bistoni; G Fadda; P Marone; M T Montagna; S Oliveri; L Polonelli; R Rigoli; I Mancuso; S La Face; L Masucci; L Romano; C Napoli; D Tatò; M G Buscema; C M C Belli; M M Piccirillo; S Conti; S Covan; F Fanti; C Cavanna; F D'Alò; L Pitzurra
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.